168 related articles for article (PubMed ID: 19284362)
1. Multitarget drugs: the present and the future of cancer therapy.
Petrelli A; Valabrega G
Expert Opin Pharmacother; 2009 Mar; 10(4):589-600. PubMed ID: 19284362
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Bavcar S; Argyle DJ
Vet Comp Oncol; 2012 Sep; 10(3):163-73. PubMed ID: 22882485
[TBL] [Abstract][Full Text] [Related]
3. Researchers optimistic about sea change in cancer treatment.
Stephenson J
JAMA; 2001 Jun; 285(22):2841-2. PubMed ID: 11401587
[No Abstract] [Full Text] [Related]
4. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
Camorani S; Crescenzi E; Fedele M; Cerchia L
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
Roussidis AE; Karamanos NK
In Vivo; 2002; 16(6):459-69. PubMed ID: 12494890
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinases: the main targets for new anticancer therapy.
Drevs J; Medinger M; Schmidt-Gersbach C; Weber R; Unger C
Curr Drug Targets; 2003 Feb; 4(2):113-21. PubMed ID: 12558064
[TBL] [Abstract][Full Text] [Related]
7. Receptor tyrosine kinases as targets for anticancer therapeutics.
Carlomagno F; Santoro M
Curr Med Chem; 2005; 12(15):1773-81. PubMed ID: 16029146
[TBL] [Abstract][Full Text] [Related]
8. Receptor tyrosine kinases and targeted cancer therapeutics.
Takeuchi K; Ito F
Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
[TBL] [Abstract][Full Text] [Related]
9. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
10. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
11. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.
Cepero V; Sierra JR; Giordano S
Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985
[TBL] [Abstract][Full Text] [Related]
13. Anti-epidermal growth factor receptor drugs in cancer therapy.
Ciardiello F; Tortora G
Expert Opin Investig Drugs; 2002 Jun; 11(6):755-68. PubMed ID: 12036420
[TBL] [Abstract][Full Text] [Related]
14. The RET proto-oncogene: a potential target for molecular cancer therapy.
Pützer BM; Drosten M
Trends Mol Med; 2004 Jul; 10(7):351-7. PubMed ID: 15242684
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
16. [Targeted therapies in pediatric oncology: a new therapeutic approach?].
Jubert C; Geoerger B; Grill J; Hartmann O; Vassal G
Arch Pediatr; 2006 Feb; 13(2):189-94. PubMed ID: 16298518
[TBL] [Abstract][Full Text] [Related]
17. Receptor tyrosine kinases and anticancer therapy.
Medinger M; Drevs J
Curr Pharm Des; 2005; 11(9):1139-49. PubMed ID: 15853662
[TBL] [Abstract][Full Text] [Related]
18. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
19. Cancer stromal targeting (CAST) therapy.
Matsumura Y
Adv Drug Deliv Rev; 2012 Jun; 64(8):710-9. PubMed ID: 22212902
[TBL] [Abstract][Full Text] [Related]
20. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers.
Sharma PS; Sharma R; Tyagi T
Curr Pharm Des; 2009; 15(7):758-76. PubMed ID: 19275641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
